XANTUS-EL, Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Noninterventional Study

Trial Profile

XANTUS-EL, Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Noninterventional Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Adverse reactions
  • Acronyms XANTUS-EL
  • Sponsors Bayer
  • Most Recent Events

    • 30 Aug 2017 Results of pooled analysis of three observational studies (XANTUS, XANAP and XANTUS-EL) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 25 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 15 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top